The roles of patient groups in fostering cancer research

As more patients with oncogene-driven non-small-cell lung cancer are treated with targeted therapies, they are joining forces online to form groups that provide support, education and advocacy focused on specific oncogenes. Herein, we discuss how the involvement of these groups in patient-partnered research can benefit both patients and lung cancer research.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Sequist, L. V. & Neal, J. W. Personalized, genotype-directed therapy for advanced non-small cell lung cancer. UpToDate https://www.uptodate.com/contents/personalized-genotype-directed-therapy-for-advanced-non-small-cell-lung-cancer (2019).

  2. 2.

    Freeman-Daily, J. ROS1+ cancer patients partner to increase research. Updates and Insights Blog www.cancer.gov/about-nci/organization/ccg/blog/2017/ros1-patient-driven-research (2017).

  3. 3.

    Scheffler, M. “[The ROS1ders] definitely know more about the disease, about the genetics of ROS1, about the treatments of ROS1, than 99.5% of my colleagues in Germany.” Excerpt from panel discussion “How to deal with diversity early on: Personalised early clinical trials” at the 2019 annual meeting of European Society for Clinical Oncology, Barcelona, Spain (2019).

  4. 4.

    @JackWestMD. “Time to highlight that we are now in an era when pts w/rare cancers are increasingly likely to know more than docs, even very good ones, about their dzs. This @ros1cancer page on Drugs to Treat ROS1+ NSCLC deserves its place at top of Google search: bit.ly/ROS1Rxs #LCSM.” Twitter https://twitter.com/JackWestMD/status/989287575469805568 (2018).

  5. 5.

    Camidge, D. R. & Freeman-Daily, J. The ROS1ders Interview Dr Ross Camidge, produced by GO2 Foundation for Lung Cancer. YouTube, www.youtube.com/watch?v=Hs3a9gjqzIA (2019).

  6. 6.

    Freeman-Daily, J. et al. “The Global ROS1 Initiative: a patient-researcher partnership generating open-source, oncogene-driven cancer models and data.” Poster presentation at the 2018 annual meeting of the American Association of Cancer Research, Chicago, IL (2018).

  7. 7.

    Neel, D. S. et al. Differential subcellular localization regulates oncogenic signaling by ROS1 kinase fusion proteins. Cancer Res. 79, 546–556 (2019).

    CAS  Article  Google Scholar 

  8. 8.

    McCoach, C. E. et al. Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer. Clin. Cancer Res. 24, 3334–3347 (2018).

    CAS  Article  Google Scholar 

  9. 9.

    Davies, K. D. et al. Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples. J. Thorac. Oncol. 13, 1474–1482 (2018).

    Article  Google Scholar 

  10. 10.

    Patil, T. et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J. Thorac. Oncol. 13, 1717–1726 (2018).

    Article  Google Scholar 

  11. 11.

    Elkins, I. et al. Project PRIORITY: A patient-founded and patient-driven research partnership to gather real-world data on EGFR-positive lung cancer [abstr MA16.01]. Presented at the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference on Lung Cancer (WCLC 2019), Barcelona, Spain (2019).

  12. 12.

    LUNGevity Foundation. Partner Awards: ALK-positive lung cancer transformational research awards. lungevity.org https://lungevity.org/research/translational-science-research-grant-programs/funded-projects/partner-awards (2018).

Download references

Acknowledgements

The authors thank the members of The ROS1ders, our research partners (the GO2 Foundation for Lung Cancer, the Addario Lung Cancer Medical Institute, Champions Oncology and LUNGevity Foundation); R. Doebele and R. Camidge of the University of Colorado; C. Lovly of Vanderbilt University; A. van der Wekken of the University Medical Center, Groningen; L. Drayer and M. Smelt of the Hanze University of Applied Science, Groningen; the pharmaceutical companies who make treatments for ROS1-positive cancers; and the network of patients, caregivers, advocates, volunteers, researchers, clinicians, non-profit organizations and donors who make our work possible.

Author information

Affiliations

Authors

Consortia

Corresponding author

Correspondence to Merel Hennink.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Related links

ALK Positive: https://www.alkpositive.org/

ALK Positive on Facebook: https://www.facebook.com/groups/ALKPositive/

EGFR Resisters Lung Cancer Patient Group on Facebook: https://www.facebook.com/groups/EGFRResisters/

EGFR Resisters: https://egfrcancer.org/

Exon 20 group: https://exon20group.org/

The EGFR Exon 20 Support Group on Facebook: https://www.facebook.com/groups/136311127056022/

The ROS1ders Patient Group on Facebook “ROS1 Positive (ROS1+) Cancer”: https://www.facebook.com/groups/ROS1cancer/

The ROS1ders website: https://ros1cancer.com/

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hennink, M., Vandeweyer, G. & Freeman-Daily, J. The roles of patient groups in fostering cancer research. Nat Rev Clin Oncol 17, 65–66 (2020). https://doi.org/10.1038/s41571-019-0314-1

Download citation

Search

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing